The FDA is frequently attacked by those who back its role in regulation but regret that this administration is too lax and on the other side those who think that regulation impairs innovation by increasing delays and costs.
This piece is quite useful and well written.
http://www.medpagetoday.com/GarySchwitzer/31999
Do patients value improvements in progression-free survival?
Il y a 1 heure
Aucun commentaire:
Enregistrer un commentaire